NewsRoom Articles - BioMedWire (BMW)

ThursdayMar 19, 2026 10:00 am

Study Finds That Marijuana Legalization Lowers Crime Rates

David Eby, the Premier of British Columbia, has revealed that a wide range of American healthcare workers, including doctors, nurse practitioners and nurses have flocked to the Canadian province in search of employment and have secured jobs. Speaking at BC Children’s Hospital on Tuesday, the premier pointed out that the progressive social values, lifestyle and public healthcare system have been instrumental in attracting U.S.-trained medical workers to B.C. He added that the province respected science while making public health policies, has a high standard of living and respects reproductive rights. These, he said, have made the province an attractive place for healthcare workers from America. He highlighted that the…

WednesdayMar 18, 2026 11:15 am

Earth Science Tech Inc. (ETST) Builds Telehealth, Pharmacy Links in Evolving Digital Care

Patients increasingly prefer access, speed and convenience, but healthcare systems also need better coordination, safer medication workflows and clearer continuity of care. DelveInsights has projected that the global telehealth market will reach $2 trillion by 2034, driven by a digital healthcare transformation. ETST is not approaching telehealth as a standalone app or referral layer but as part of a broader operating structure that includes medication fulfillment capacity and patient-facing services. Telehealth is evolving from a simple video visit into something far more comprehensive: a connected care model that can move a patient from consultation to prescription, fulfillment and follow-up inside…

WednesdayMar 18, 2026 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Innovation Through Platform Science and Expanding Therapeutic Pipeline

High-quality development platforms and translational research frameworks have become essential tools in rare-disease biotechnology. Soligenix is leveraging its platform science to expand the therapeutic reach of its development programs and explore additional disease indications. The broader emphasis of Soligenix’s platform science approach is to maximize the scientific value of its research infrastructure. Medical progress has transformed the treatment of many common illnesses, yet thousands of rare diseases still lack effective therapies. Companies working at the intersection of biotechnology innovation and rare disease research are increasingly focused on addressing these gaps, including Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing and…

TuesdayMar 17, 2026 10:00 am

Mirror-Image Amino Acid Shows Promise in Starving Cancer Cells

Most existing cancer treatments not only attack cancer cells but also adversely impact healthy body cells. The resultant damage to healthy tissues usually triggers side effects that often become severe, necessitating discontinuation of therapy or making quality of life worse. Scientists have been looking for better treatments that only impact malignant cells and leave healthy cells unaffected. A new preclinical study documents one such discovery leveraging the use of a mirror-image molecule. The study, conducted by a team based at Marburg University and University of Geneva, created a molecule similar to a naturally occurring amino acid referred to as cysteine. It contains sulfur within its composition. The researchers found that some cancers have a transporter on their…

MondayMar 16, 2026 9:45 am

Investing in Innovation: Evaluating the Clinical and Commercial Potential of LB-100 and Liora’s Proton Therapy

LIXTE Biotechnology Holdings and Liora Technologies recently joined forces to soon offer a real fight against cancer. LIXTE develops LB-100, a drug that enhances the effectiveness of cancer treatments, while Liora has developed a unique cancer treatment that’s believed to be more affordable, precise, and efficient than many traditional options. Together, this pair of products have incredible clinical and commercial potential, to both help the businesses succeed, while also offering better outcomes for patients suffering from cancer. LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company, and the company’s subsidiary, Liora Technologies, both develop cancer therapies that, when combined,…

FridayMar 13, 2026 10:00 am

Microbial Ecosystems Play a Big Role in the Efficacy of Cancer Immunotherapy

Significant strides have been made in leveraging checkpoint inhibitor therapy to combat a number of cancers over the recent years. However, not all malignancies respond to these therapies, and those that do often become resistant, or are discontinued due to adverse reactions within the immune system. Now, researchers have shown that gut microbiota are one of the key factors influencing the success of immunotherapy targeting PD-L1 and PD-1 gene expression. The study was published in the journal Cancer Biology and Medicine. The research team undertook a comprehensive review focused on seeking to understand how microbial ecosystems within the gut impact how patients respond to checkpoint inhibitors targeting PD-L1 and PD-1. They analyzed clinical trials, preclinical studies and available multi-omics data to ascertain how bacterial…

FridayMar 13, 2026 9:00 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands LB 100 Development Through Strategic Academic and Pharma Partnerships

LIXTE recently expanded its ovarian clear cell cancer trial in partnership with MD Anderson and GSK The company operates at the nexus of targeted cancer biology and combination therapy innovation These partnerships help underscore LIXTE’s broader strategy: enhancing established cancer treatments through its first-in-class compound LB 100 LIXTE Biotechnology Holdings (NASDAQ: LIXT) continues to promote its lead oncology asset, LB 100, through a partnership-driven model designed to accelerate development and improve scientific validation. Recently, the company announced the expansion of its ongoing clinical collaboration with the University of Texas MD Anderson Cancer Center and GSK plc to evaluate LB 100…

ThursdayMar 12, 2026 10:00 am

California Chooses to Take on Federal Government on Public Health Issues

California, led by Democratic governor Gavin Newsom, has decided to break with the federal positions on public health and has resolved to stand by policies backed by science rather than the controversial positions being taken by the federal government through its health secretary R. F. Kennedy Jr. Many see the policies being pushed by the federal administration as misinformation and politicization of matters that should entirely be based on rigorous science. For example, Kennedy has linked autism to vaccination despite the lack of solid scientific data backing such a claim. Policy decisions like changing vaccine mandates have been seen as taking the country backwards from the…

WednesdayMar 11, 2026 11:15 am

Earth Science Tech Inc. (ETST) Is Operating a Diversified Portfolio of Businesses in the Pharmaceutical, Healthcare, Telemedicine and Consumer Markets

Earth Science Tech is a holding company that acquires and manages businesses in several markets, emphasizing execution, capital discipline, and long-term value creation across the company’s various platforms. The company generally focuses on controlling interests in companies where disciplined scaling, regulatory compliance, and operational oversight can drive growth. The team at Earth Science Tech is led by executives with years of experience in areas like finance, business, real estate, digital infrastructure, and others. Earth Science Tech (OTC: ETST), a strategic holding company, operates a portfolio in the pharmaceutical, telemedicine, healthcare and consumer markets. The company strives to build value by…

WednesdayMar 11, 2026 10:30 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Appoints TMS, Neuroplasticity Researcher Joshua Brown MD, PhD, as Chief Medical Innovation Officer

Prof. Brown is a leading researcher in Transcranial Magnetic Stimulation (“TMS”) and currently serves as President of the Clinical TMS Society. His work explores how brain stimulation therapies can be enhanced through neuroplasticity-focused medications, including D-cycloserine, a component of NRx’s investigational drug NRX‑101. Brown previously received funding from the Defense Advanced Research Projects Agency (“DARPA”) to study treatments for military personnel suffering from Post-Traumatic Stress Disorder (“PTSD”). NRx is investigating a treatment approach combining ketamine, TMS, and hyperbaric oxygen in patients with PTSD and depression, with trials planned through its HOPE Therapeutics clinic network. The appointment reflects NRx’s evolving strategy…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Study Finds That Marijuana Legalization Lowers Crime Rates

Earth Science Tech Inc. (ETST) Builds Telehealth, Pharmacy Links in Evolving Digital Care

Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Innovation Through Platform Science and Expanding Therapeutic Pipeline

Mirror-Image Amino Acid Shows Promise in Starving Cancer Cells

Investing in Innovation: Evaluating the Clinical and Commercial Potential of LB-100 and Liora’s Proton Therapy

Microbial Ecosystems Play a Big Role in the Efficacy of Cancer Immunotherapy

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands LB 100 Development Through Strategic Academic and Pharma Partnerships

California Chooses to Take on Federal Government on Public Health Issues

Earth Science Tech Inc. (ETST) Is Operating a Diversified Portfolio of Businesses in the Pharmaceutical, Healthcare, Telemedicine and Consumer Markets

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Appoints TMS, Neuroplasticity Researcher Joshua Brown MD, PhD, as Chief Medical Innovation Officer

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search